2BUUY-HANSELTAGV2Hansel Tracker

Hansel Tag Last updated 17 March, 2026 This article will cover: ● Device Overview ● Activation Steps and Use ● Operating Characteristics ● Support Device Overview The Hansel Tag is a Bluetooth® Low Energy (BLE) asset tracking device designed to help hospitals and medical device distributors track surgical instrument trays and equipment. Each tag broadcasts a secure Bluetooth identifier that can be detected by the Hansel mobile application and Hansel infrastructure to provide real-time asset visibility. Tags are shipped in a dormant state to preserve battery life and must be activated before use. Step 1: Tag Activation Hansel Tags ship powered off to conserve battery life during storage and shipping. To activate the tag: 1. Hold a magnet near the top of the tag. 2. Keep it there for 2-3 seconds to ensure activation. 3. The tag will begin broadcasting. Step 2: Assign Tag to an Asset in Hansel 1. Open the Hansel mobile application. 2. Navigate to More Tab → Hansel Tag Management → Assign Hansel Tag. 3. Select Begin Hansel Tag Scan... 4. Tap smartphone to the top of the tag. 5. Search the available asset to assign the tag to. Step 3: Attach Hansel Tag to the Instrument Tray 1. Locate a section of the tray away from instruments if possible. 2. Choose a placement on an upper level of the tray, if two exist. 3. Use a high temperature PEEK zip tie to attach the tag on the tray surface. 4. Secure the zip tie tightly. Choose slotted holes in close proximity to each other. 5. Snip the excess zip tie material flush with the locking mechanism. Tag attachment inside a tray away from instruments. Operating Characteristics ● Bluetooth® Low Energy (BLE) ● Up to 150 m communication range (open area, line of sight) ● Operating temperature designed for harsh environments ● 2 years 9 months battery life under normal asset-tracking use FCC Compliance Disclaimer (Class B) This equipment has been tested and found to comply with the limits for a Class B digital device, pursuant to part 15 of the FCC Rules. These limits are designed to provide reasonable protection against harmful interference in a residential installation. This equipment generates, uses and can radiate radio frequency energy and, if not installed and used in accordance with the instructions, may cause harmful interference to radio communications. However, there is no guarantee that interference will not occur in a particular installation. If this equipment does cause harmful interference to radio or television reception, which can be determined by turning the equipment off and on, the user is encouraged to try to correct the interference by one or more of the following measures: ● Reorient or relocate the receiving antenna. ● Increase the separation between the equipment and receiver. ● Connect the equipment into an outlet on a circuit different from that to which the receiver is connected. ● Consult the dealer or an experienced radio/TV technician for help. This device complies with Part 15 of the FCC Rules. Operation is subject to the following two conditions: (1) this device may not cause harmful interference, and (2) this device must accept any interference received, including interference that may cause undesired operation. Please note that changes or modifications not expressly approved by the party responsible for compliance could void the user’s authority to operate the equipment. FCC RF Exposure Statement (SAR - Limb) This device complies with FCC radiation exposure limits for uncontrolled environments. The Specific Absorption Rate (SAR) limit for extremities (hands, wrists, feet, ankles) is 4.0 W/kg averaged over 10 g of tissue. SAR compliance for limb-worn use was demonstrated via calculations using the device’s highest certified transmit power, with the device positioned directly against the limb at 0 mm separation, in accordance with FCC evaluation procedures specified in 47 C.F.R. § 1.1310(c) and § 2.1093, and consistent with OET and KDB guidance.

Dated: February 19, 2026 Nemko North America, Inc. 303 River Road Ottawa ON K1V 1H2 Canada Covered Equipment Certification Attestation Letter Applicant: Hansel Medical Inc FCC ID: 2BUUY-HANSELTAGV2 The applicant certifies that the equipment for which authorization is sought is not “covered” equipment prohibited from receiving an equipment authorization pursuant to section §2.903 of the FCC rules. This includes certifying that the equipment for which authorization is sought does not include cybersecurity or anti-virus software produced or provided by Kaspersky Lab, Inc. or any of its successors and assignees, including equipment with integrated Kaspersky Lab, Inc. (or any of its successors and assignees) cybersecurity or anti-virus software pursuant to DA-24-886 and KDB 986446 D01 Covered Equipment Guidance section B(2a). Note: If the equipment for which the applicant seeks authorization is produced by any of the entities identified on the current FCC Covered List, the applicant should include an explanation on why the equipment is not “covered” equipment. The applicant certifies that, as of the date of the filing of the application, the applicant is not identified on the Covered List as an entity producing “covered” equipment. Sincerely, Signature: Name: Gregory Prosser Title: CEO Company: Hansel Medical Inc. Address: 10661 Steppington Dr #3088, Dallas TX 75230 Phone: 636-299-8809 Email: [email protected]

* The agent’s name must exactly match the primary contact person listed in the FRN registration details. ** The Agent FRN may be the same as the applicant’s if the agent and the applicant are the same U.S.-based legal entity. Dated: April 2, 2026 Nemko North America, Inc. 303 River Road Ottawa ON K1V 1H2 Canada U.S. Agent Designation for Service of Process Attestation Letter FCC ID: 2BUUY-HANSELTAGV2 Applicant FRN: 0037994035 This letter serves as a formal designation, pursuant to §2.911(d)(7) of the FCC Rules, of the following U.S. Agent for Service of Process for the equipment under application: U.S. Agent for Service of Process: • Company Name: Hansel Medical Inc. • Physical U.S. Company Address: 10661 Steppington Dr #3088, Dallas TX 75230 USA • Agent Name*: Gregory Prosser • Agent Email Address: [email protected] • Agent FRN**: 0037994035 The above listed designated agent hereby acknowledges and accepts the obligation for service of process on behalf of the applicant signed below. The applicant further acknowledges and accepts its obligation to maintain a U.S. Agent for Service of Process for a minimum period of one year following either: • Permanent termination of all marketing and importation activities within the U.S. for the applicable equipment by the grantee. • The conclusion of any Commission-related administrative or judicial proceeding involving the equipment, whichever occurs later. Applicant/Agent Signed: Signature: Name: Gregory Prosser Title: CEO Company: Hansel Medical Inc. Address: 10661 Steppington Dr. #3088, Dallas TX 75230 Phone: 636-299-8809 Email: [email protected]

Dated: April 14, 2026 Nemko North America, Inc. 303 River Road, Ottawa, Ontario, Canada K1V 1H2 Attn: Director of Certification Request for Special Confidentiality – FCC FCC ID: 2BUUY-HANSELTAGV2 Pursuant to FCC 47 CFR 0.457(d)(1)(ii) and 0.459 and FCC guidance published in KDB 726920, we hereby request confidential treatment of information accompanying this application as outlined below. We request the exhibits selected below as long term confidential (LTC) be withheld from public view permanently: Selection 1 Exhibit name ☒ Internal Photos The device’s internal circuitry and components are not accessible to end users and are designed to be serviced solely by authorized technicians under NDA. All product sales must be governed by an NDA that protects proprietary information, including internal photographs. A sample NDA is included with this application. Our company has made substantial investments in the development of this innovative product, which represents a first-of-its-kind solution in the industry. Public disclosure of the technical details would compromise our competitive edge and could result in significant financial harm. Safeguarding the confidentiality of our design is critical to protecting our intellectual property. The information provided includes trade secrets and proprietary data not customarily disclosed to the public. Unauthorized disclosure could adversely impact our business and provide competitors with an unfair advantage. Sincerely, Signature: Name: Gregory Prosser Title: CEO Company: Hansel Medical Inc. Address: 10661 Steppington Dr., #3088, Dallas TX 75230 Phone: 636-299-8809 Email: [email protected] 1 - These items require further information to be provided to TCB before permanent confidentiality will be extended to these exhibits. Please refer to FCC KDB 726920 and review section II, 3) regarding specific information (NDA) that must accompany these requests.

NON-DISCLOSURE AGREEMENT THIS AGREEMENT (the "Agreement”) is entered into on this ____day of ______________, ________, by and between Hansel Medical Inc., located at 10661 Steppington Dr., # 3088, Dallas, TX 75230, and (the” Disclosing Party”), and ____________________________________with an address at ________________________________________________________________(the “Receiving Party”). The Receiving Party hereto desires to participate in discussions regarding proprietary industry specific business applications, models, processes, procedures, assets, equipment, tactics, technology, services and suppliers including, but not limited to, topics detailed in Exhibit A. (the “Transaction”). During these discussions, Disclosing Party may share certain proprietary information with the Receiving Party. Therefore, in consideration of the mutual promises and covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 1. Definition of Confidential Information. (a) For purposes of this Agreement, “Confidential Information” means any data or information that is proprietary to the Disclosing Party and not generally known to the public, whether in tangible or intangible form, in whatever medium provided, whether unmodified or modified by Receiving Party or its Representatives (as defined herein), whenever and however disclosed, including, but not limited to: (i) any marketing strategies, plans, financial information, or projections, operations, sales estimates, business plans and performance results relating to the past, present or future business activities of such party, its affiliates, subsidiaries and affiliated companies; (ii) plans for products or services, and customer or supplier lists; (iii) any scientific or technical information, invention, design, process, procedure, formula, improvement, technology or method; (iv) any concepts, reports, data, know-how, works-in-progress, designs, development tools, specifications, computer software, source code, object code, flow charts, databases, inventions, information and trade secrets; (v) any other information that should reasonably be recognized as confidential information of the Disclosing Party; and (vi) any information generated by the Receiving Party or by its Representatives that contains, reflects, or is derived from any of the foregoing. Confidential Information need not be novel, unique, patentable, copyrightable or constitute a trade secret in order to be designated Confidential Information. The Receiving Party acknowledges that the Confidential Information is proprietary to the Disclosing Party, has been developed and obtained through great efforts by the Disclosing Party and that Disclosing Party regards all of its Confidential Information as trade secrets. (b) Notwithstanding anything in the foregoing to the contrary, Confidential Information shall not include information which: a) was lawfully possessed, as evidenced by the Receiving Party’s records, by the Receiving Party prior to receiving the Confidential Information from the Disclosing Party; (b) becomes rightfully known by the Receiving Party from a third-party source not under an obligation to Disclosing Party to maintain confidentiality; (c) is generally known by the public through no fault of or failure to act by the Receiving Party inconsistent with its obligations under this Agreement; (d) is required to be disclosed in a judicial or administrative proceeding, or is otherwise requested or required to be disclosed by law or regulation, although the requirements of paragraph 4 hereof shall apply prior to any disclosure being made; and (e) is or has been independently developed by employees, consultants or agents of the Receiving Party without violation of the terms of this Agreement, as evidenced by the Receiving Party’s records, and without reference or access to any Confidential Information. 2. Disclosure of Confidential Information. 2 From time to time, the Disclosing Party may disclose Confidential Information to the Receiving Party. The Receiving Party will: (a) limit disclosure of any Confidential Information to its directors, officers, employees, agents or representatives (collectively “Representatives”) who have a need to know such Confidential Information in connection with the current or contemplated business relationship between the parties to which this Agreement relates, and only for that purpose; (b) advise its Representatives of the proprietary nature of the Confidential Information and of the obligations set forth in this Agreement, require such Representatives to be bound by written confidentiality restrictions no less stringent than those contained herein, and assume full liability for acts or omissions by its Representatives that are inconsistent with its obligations under this Agreement; (c) keep all Confidential Information strictly confidential by using a reasonable degree of care, but not less than the degree of care used by it in safeguarding its own confidential information; and (d) not disclose any Confidential Information received by it to any third parties (except as otherwise provided for herein). 3. Use of Confidential Information. The Receiving Party agrees to use the Confidential Information solely in connection with the current or contemplated business relationship between the parties and not for any purpose other than as authorized by this Agreement without the prior written consent of an authorized representative of the Disclosing Party. No other right or license, whether expressed or implied, in the Confidential Information is granted to the Receiving Party hereunder. Title to the Confidential Information will remain solely in the Disclosing Party. All use of Confidential Information by the Receiving Party shall be for the benefit of the Disclosing Party and any modifications and improvements thereof by the Receiving Party …

Text truncated - open the document above for the full version.

Dated: February 19, 2026uary 21 st , 2026 Nemko North America, Inc. 303 River Road, Ottawa, Ontario, Canada K1V 1H2 Attn: Director of Certification Appointment of Agent for FCC Certification Application Dear Director of Certification, This letter formally appoints Spencer Zhong of Nemko Canada, Inc. located at 303 River Road, Ottawa, Ontario, Canada K1V 1H2, as our authorized agent to represent us in the application process for equipment certification. We confirm that the submitted documents accurately depict the device or system seeking certification. Additionally, we guarantee that all units produced, imported, or marketed, as defined by FCC regulations, will possess a label identical to the one submitted with this application. By signing below, we certify that neither our company nor any party involved in the application is subject to denial of federal benefits, including FCC benefits, as outlined in Section 5301 of the Anti- Drug Abuse Act of 1988 (21 U.S.C. §862) due to a conviction for possession or distribution of a controlled substance. Furthermore, no party involved in the application, as defined in 47 CFR 1.2002 (b), is subject to denial of federal benefits, including FCC benefits. We attest to the truth and accuracy of the information provided to the FCC to the best of our knowledge (47 CFR 2.911 (d)) and acknowledge our responsibilities as a grantee regarding certified equipment (47 CFR 2.909). In instances where our authorized agent signs the application for certification on our behalf, we understand that Nemko North America, Inc. remains solely responsible for adhering to the terms and conditions for certification as specified by Nemko Canada Inc. Agency agreement expiration date: January 21, 2027 *Up to 12 months Sincerely, Signature: Name: Gregory Prosser Title: CEO Company: Hansel Medical Inc. Address: 10661 Steppington Dr. #3088, Dallas TX 75230 Phone: 636-299-8809 Email: [email protected]

Dated: February 19, 2026 Nemko North America, Inc. 303 River Road, Ottawa, Ontario, Canada K1V 1H2 Attn: Director of Certification Confidentiality Request Letter – FCC FCC ID: 2BUUY-HANSELTAGV2 Pursuant to FCC 47 CFR 0.457(d)(1)(ii) and 0.459 and FCC guidance published in KDB 726920, we hereby request confidential treatment of information accompanying this application as outlined below. Long Term Confidentiality (LTC) request We request the exhibits selected below as long term confidential be withheld from public view permanently: Selection Exhibit name ☒ Block Diagrams ☒ Operation Description / Theory of Operation ☒ Parts List & Placement / BOM ☒ Schematics Justification for Confidentiality The development of this product represents a significant investment and a strategic competitive differentiator for our company. Unrestricted public access to its design specifics would negate this hard-earned advantage, leading to considerable financial hardship. The content herein contains trade secrets and proprietary information not typically released to the public. Disclosure of this information could severely impact the applicant and provide an unfair advantage to competitors. The Applicant acknowledges that, under Rule 0.457(d)(1)(ii), this Application and all associated materials will not be disclosed before the Grant date. Sincerely, Signature: Name: Gregory Prosser Title: CEO Company: Hansel Medical Inc. Address: 10661 Steppington Dr #3088, Dallas TX 75230 Phone: 636-299-8809 Email: [email protected]

External Photographs Exhibit Product: Hansel Tag FCC ID: 2BUUY-HANSELTAGV2 Applicant: Hansel Medical Inc Date: March 30, 2026 Purpose This exhibit provides color photographs of the external appearance of the subject device, as required by FCC §2.1033(b)(7). The photos demonstrate the external design, dimensions, and location of regulatory labels and antennas (if visible). Notes • All external photographs are of the final production version of the device. • No digital modifications were made, aside from cropping or brightness correction to improve visibility. 1. Top View 2. Bottom View 3. Side View

1 A 2 3 4 5 678 12 3 4 5 678 B C D E F A B C D E F BRASH PRODUCT DEVELOPMENT INC. PROPRIETARY AND CONFIDENTIAL THE CONTENTS OF THIS DRAWING, IS THE SOLE PROPERTY OF BRASH INC. ANY REPRODUCTION IN PART OR AS A WHOLE WITHOUT THE WRITTEN PERMISSION OF BRASH INC IS PROHIBITED. Drawing notes: DESCRIPTION DRAWN BY APPROVED BY PART NO. PART NAME DATE DATE FINISH MATERIAL 2450 Dot-8mm - 2450 Dot-Base-8mm v3 Markus Melcher 2026-03-09 Steel STEP AP242 Text height: 1.2 mm

www.nemko.com Nemko Canada Inc., a testing laboratory, is accredited by ANSI National Accreditation Board (ANAB). The tests included in this report are within the scope of this accreditation. The ANAB symbol is an official symbol of the ANSI National Accreditation Board, used under license. ANAB File Number: AT-3195 (Ottawa); AT-3193 (Pointe-Claire); AT-3194 (Cambridge) FCC and RSS-102 Annex C – SAR Exemption; Date: May 2021 C h o o s e S c a n d i n a v i a n t r u s t RADIO TEST REPORT Type of assessment: SAR Exemption report Manufacturer: Hansel Medical Inc. Product description: Model: Hansel Tracker V2 FCC ID: 2BUUY-HANSELTAGV2 Specifications:  FCC 47 CFR Part 2 Subpart J, §2.1093  FCC KDB 447498 D01 General RF Exposure Guidance v06 RSS-102 Annex C Attestation: I attest that the radiocommunication apparatus meets the exemption from the routine evaluation limits in these standards; that the Technical Brief was prepared and the information contained therein is correct; that the device evaluation was performed or supervised by me; that applicable measurement methods and evaluation methodologies have been followed; and that the device meets the SAR and/or RF field strength limits of the above standards. Date of issue: April 2, 2026 Andrey Adelberg, Senior EMC/RF Specialist Prepared by Signature Report reference ID: SAR Exemption report Page 2 of 5 Lab locations Company name Nemko Canada Inc. Facilities Ottawa site: 303 River Road Ottawa, Ontario Canada K1V 1H2 Tel: +1 613 737 9680 Fax: +1 613 737 9691 Montréal site: 292 Labrosse Avenue Pointe-Claire, Québec Canada H9R 5L8 Tel: +1 514 694 2684 Fax: +1 514 694 3528 Cambridge site: 1-130 Saltsman Drive Cambridge, Ontario Canada N3E 0B2 Tel: +1 519 650 4811 Almonte site: 1500 Peter Robinson Road West Carleton, Ontario Canada K0A 1L0 Tel: +1 613 256-9117 Test site identifier Organization Ottawa/Almonte Montreal Cambridge FCC: CA2040 CA2041 CA0101 ISED: 2040A-4 2040G-5 24676 Website www.nemko.com Limits of responsibility Note that the results contained in this report relate only to the items tested and were obtained in the period between the date of initial receipt of samples and the date of issue of the report. This test report has been completed in accordance with the requirements of ISO/IEC 17025. All results contained in this report are within Nemko Canada’s ISO/IEC 17025 accreditation. Copyright notification Nemko Canada Inc. authorizes the applicant to reproduce this report provided it is reproduced in its entirety and for use by the company’s employees only. Any use which a third party makes of this report, or any reliance on or decisions to be made based on it, are the responsibility of such third parties. Nemko Canada Inc. accepts no responsibility for damages, if any, suffered by any third party as a result of decisions made or actions based on this report. © Nemko Canada Inc. Report reference ID: SAR Exemption report Page 3 of 5 Table of Contents Table of Contents ......................................................................................................................................................................................................... 3 Section 1 Evaluation summary ........................................................................................................................................................................... 4 1.1 SAR exemption for standalone transmission ............................................................................................................................................................ 4 Section 1.1 SAR exemption for standalone transmission Report reference ID: SAR Exemption report Page 4 of 5 Section 1 Evaluation summary 1.1 SAR exemption for standalone transmission 1.1.1 References, definitions and limits FCC §2.1093 (2) The SAR limits for general population/uncontrolled exposure are 0.08 W/kg, as averaged over the whole body, and a peak spatial-average SAR of 1.6 W/kg, averaged over any 1 gram of tissue (defined as a tissue volume in the shape of a cube). Exceptions are the parts of the human body treated as extremities, such as hands, wrists, feet, ankles, and pinnae, where the peak spatial-average SAR limit is 4 W/kg, averaged over any 10 grams of tissue (defined as a tissue volume in the shape of a cube). Exposure may be averaged over a time period not to exceed 30 minutes to determine compliance with general population/uncontrolled SAR limits. FCC KDB 447498 D01 4.3.1 Standalone SAR test exclusion considerations The SAR-based exemption formula of §1.1307(b)(3)(i)(B), repeated here, applies for single fixed, mobile, and portable RF sources with available maximum time-averaged power or effective radiated power (ERP), whichever is greater, of less than or equal to the threshold P th (mW). This method shall only be used at separation distances from 0.5 cm to 40 cm and at frequencies from 0.3 GHz to 6 GHz (inclusive). P th is given by formula 푃 푡ℎ ( 푚푊 ) = { 퐸푅푃 20 푐푚 ( 푑 20 푐푚 ⁄) 푥 푑≤20 푐푚 퐸푅푃 20 푐푚 20 푐푚<푑 ≤40 푐푚 where 푥=−log 10 ( 60 퐸푅푃 20 푐푚 √ 푓 ) Table 1.1-1: Example Power Thresholds (mW) Separation: 5 mm 10 mm 15 mm 20 mm 25 mm 30 mm 35 mm 40 mm 45 mm 50 mm 300 MHz 39 65 88 110 129 148 166 184 201 217 450 MHz 22 44 67 89 112 135 158 180 203 226 835 MHz 9 25 44 66 90 116 145 175 207 240 1900 MHz 3 12 26 44 66 92 122 157 195 236 2450 MHz 3 10 22 38 59 83 111 143 179 219 3600 MHz 2 8 18 32 49 71 96 125 158 195 5800 MHz 1 6 14 25 40 58 80 106 136 169 Notes: Values in the table are in mW For mobile devices that are not exempt per Table 1 [of §1.1307(b)(1)(i)(C)] at distances from 20 cm to 40 cm and in 0.3 GHz to 6 GHz, evaluation of compliance with the exposure limits in §1.1310 is necessary if the ERP of the device is greater than ERP 20 cm in Formula below [repeated from §2.1091(c)(1); also in §1.1307(b)(1)(i)(B)]. 푃 푡ℎ ( 푚푊 ) =퐸푅푃 20 푐푚 ( 푚푊 ) ={ 2040푓 0.3 퐺퐻푧 ≤푓<1.5 퐺퐻푧 3060 1.5 퐺퐻푧 ≤푓≤6 퐺퐻푧 Table 1.1-2: Thresholds for single RF sources subject to…

Text truncated - open the document above for the full version.

www.nemko.com Nemko Canada Inc., a testing laboratory, is accredited by ANSI National Accreditation Board (ANAB). The tests included in this report are within the scope of this accreditation. The ANAB symbol is an official symbol of the ANSI National Accreditation Board, used under license. ANAB File Number: AT-3195 (Ottawa); AT-3193 (Pointe-Claire); AT-3194 (Cambridge) FCC 15.247; Date: October 21, 2025 C h o o s e S c a n d i n a v i a n t r u s t RADIO TEST REPORT Report ID: Project number: REP142038 PRJ0091820 Type of assessment: Final product testing Type of radio equipment: Bluetooth Device Equipment class: DTS - digital transmission systems Applicant: Product marketing name (PMN): Hansel Medical Inc. Hansel Tracker Model number /HVIN(s): FCC identifier: V2 FCC ID: 2BUUY-HANSELTAGV2 Specifications: FCC 47 CFR Part 15 Subpart C, §15.247 Date of issue: April 2, 2026 Dhara Patel, EMC/RF Specialist Tested by Signature David Duchesne, EMC/RF Lab Manager Reviewed by Signature Report reference ID: REP142038 Page 2 of 32 Lab locations Company name Nemko Canada Inc. Facilities Ottawa site: 303 River Road, Ottawa, ON, Canada, K1V 1H2 Tel: +1 613 737 9680 Test site registration number: CA2040 Montréal site: 292 Labrosse Avenue, Pointe-Claire, QC, Canada, H9R 5L8 Tel: +1 514 694 2684 Test site registration number: CA2041 Cambridge site: 1-130 Saltsman Drive, Cambridge, ON, Canada, N3E 0B2 Tel: +1 519 650 4811 Test site registration number: CA0101 Website www.nemko.com Limits of responsibility Note that the results contained in this report relate only to the items tested and were obtained in the period between the date of initial receipt of samples and the date of issue of the report. This test report has been completed in accordance with the requirements of ISO/IEC 17025. All results contained in this report are within Nemko Canada’s ISO/IEC 17025 accreditation. Copyright notification Nemko Canada Inc. authorizes the applicant to reproduce this report provided it is reproduced in its entirety and for use by the company’s employees only. Any use which a third party makes of this report, or any reliance on or decisions to be made based on it, are the responsibility of such third parties. Nemko Canada Inc. accepts no responsibility for damages, if any, suffered by any third party as a result of decisions made or actions based on this report. © Nemko Canada Inc. Report reference ID: REP142038 Page 3 of 32 Table of Contents Table of Contents ......................................................................................................................................................................................................... 3 Report summary ................................................................................................................................................................................. 4 1.1 Test specifications .................................................................................................................................................................................................... 4 1.2 Test methods ............................................................................................................................................................................................................ 4 1.3 Exclusions ................................................................................................................................................................................................................. 4 1.4 Statement of compliance .......................................................................................................................................................................................... 4 1.5 Test report revision history ....................................................................................................................................................................................... 4 Engineering considerations ................................................................................................................................................................. 5 2.1 Modifications incorporated in the EUT for compliance ............................................................................................................................................ 5 2.2 Technical judgment ........................................................…

Text truncated - open the document above for the full version.